

WRITER'S INTERNET ADDRESS: MGARRETT@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER: 512/536-3031

COPY OF PAPERS * ORIGINALLY FILED

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE. SUITE 2400 AUSTIN. TEXAS 78701

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

February 28, 2002

FILE: UTSD:798US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

February 28, 2002

Date

Mark T. Garrett

Commissioner for Patents Washington, DC 20231

RE:

SN 09/905,670 "METHODS AND APPARATUSES FOR NAVIGATING THE

SUBARACHNOID SPACE" - Phillip D. Purdy (Client Reference: UTSMC/DAL:0798)

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (C19).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104397/MTG.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Mark T. Garrett Reg. No. 44,699

MTG/cmb

Encl: as noted

25139112.1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Phillip D. Purdy

Serial No.: 09/905,670

Filed: July 13, 2001

For: METHODS AND APPARATUSES FOR NAVIGATING THE SUBARACHNOID

SPACE

Group Art Unit: 3763

Examiner: Unknown

Atty. Dkt. No.: UTSD:798US/MTG

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date

below:

February 28, 2002

Date

Mark T. Garrett

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

25139110.1

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to

Jaworski Deposit Account No.: 50-1212/10104397/MTG.

Applicant respectfully requests that the listed documents be made of record in the present case.

these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright &

Respectfully submitted,

Mark T. Garrett Reg. No. 44,699

Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

February 28, 2002

of cerebral vasospasm," Stroke, 31:2141-2148, 2000.

25139104.1

EXA	MIN	ER:
-----	-----	-----

C19

DATE CONSIDERED:

Hamada et al., "Microcatheter intrathecal urokinase infusion into cisterna magna for prevention

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.